A phase II study of Cabazitaxel chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis

Trial Profile

A phase II study of Cabazitaxel chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Penile cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms JAVA-P
  • Most Recent Events

    • 10 Apr 2017 Status changed from recruiting to completed.
    • 02 Apr 2015 Accrual to date is 11% according to United Kingdom Clinical Research Network.
    • 09 Feb 2015 Accrual to date is 5% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top